AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19663922 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (BD Glucose Tablets)
Number of subjects: 33
Study 19663922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (Skittles)
Number of subjects: 33
Study 19663922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (Fruit to Go)
Number of subjects: 33
Study 18591549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 150
Study 18591549 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 150
Study 15810049 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGBP)
Number of subjects: 83
Study 15810049 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 83
Study 12067003 — intervention group
Group type: EXPERIMENTAL
Intervention: volatile anaesthetics (isoflurane, enflurane, sevoflurane)
Number of subjects: 1180
Study 12067003 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol anaesthesia
Number of subjects: 1180
Study 12067003 — intervention group
Group type: EXPERIMENTAL
Intervention: postoperative opioids
Number of subjects: 1180
Study 12067003 — intervention group
Group type: EXPERIMENTAL
Intervention: being a child
Number of subjects: 1180
Study 12067003 — intervention group
Group type: EXPERIMENTAL
Intervention: PONV in the early period
Number of subjects: 1180
Study 10597985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (single high dose every 4 months)
Number of subjects: 1405
Study 10597985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single high dose every 4 months)
Number of subjects: 1405
Study 8565034 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepyramine-theophylline-acetate (MTA) 8 mg/kg per day by mouth in three divided doses for 7 days
Number of subjects: 40
Study 8565034 — intervention group
Group type: COMPARATOR
Intervention: Placebo 50 microL/kg per day in three divided doses for 7 days
Number of subjects: 40
Study 8565034 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepyramine-theophylline-acetate (MTA)
Number of subjects: 40
Study 8565034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8565034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 1960549 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional hyperthermic perfusion with melphalan
Number of subjects: 69
Study 1960549 — intervention group
Group type: COMPARATOR
Intervention: Surgery (Control)
Number of subjects: 69
Study 31406997 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with 500 mg/kg resveratrol (HT+Res)
Number of subjects: 288
Study 31406997 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (HT)
Number of subjects: 288
Study 29315807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial icon of Buddha Dipamkara (Buddha of the Past)
Number of subjects: 0
Study 29315807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial icon of Buddha Maitreya (Buddha of the Future)
Number of subjects: 0
Study 29315807 — intervention group
Group type: EXPERIMENTAL
Intervention: Religion prime administered to atheists
Number of subjects: 0
Study 26892708 — intervention group
Group type: EXPERIMENTAL
Intervention: Two feet-in-the-door technique (preceded by two small requests)
Number of subjects: 0
Study 26892708 — intervention group
Group type: EXPERIMENTAL
Intervention: Single foot-in-the-door technique (preceded by one small request)
Number of subjects: 0
Study 26892708 — intervention group
Group type: COMPARATOR
Intervention: Control condition (only a 24 h stop-smoking request)
Number of subjects: 0
Study 24625704 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS over the right dorsolateral prefrontal cortex (intensity of 110% of the threshold; 3000 stimuli per protocol; 10 daily sessions) combined with partial sleep deprivation (PSD applied once per week)
Number of subjects: 19
Study 24625704 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19
Study 23171380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm and music-based therapy program
Number of subjects: 120
Study 23171380 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic riding
Number of subjects: 120
Study 23171380 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the T1 training program a year later
Number of subjects: 120
Study 20144164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 0
Study 20144164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17666169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindgren osteotomy
Number of subjects: 100
Study 17666169 — intervention group
Group type: COMPARATOR
Intervention: Distal chevron osteotomy
Number of subjects: 100
Study 16273564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 51
Study 16273564 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 51
Study 16273564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) in SIRIUS trial
Number of subjects: 51
Study 11902152 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior study of both alternatives in implicit memory tasks
Number of subjects: 0
Study 11902152 — intervention group
Group type: COMPARATOR
Intervention: Neither alternative studied
Number of subjects: 0
Study 9973914 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol (Visipaque) 270 mg I/ml
Number of subjects: 128
Study 9973914 — intervention group
Group type: COMPARATOR
Intervention: iopamidol (Iopamiron) 300 mg I/ml
Number of subjects: 128
Study 7752862 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased training via run training (ITRT) for 10 days (100% NT)
Number of subjects: 11
Study 7752862 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased training via cross-training (ITCT) for 10 days (100% NT)
Number of subjects: 11
Study 1689084 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural administration of endogenous opioids
Number of subjects: 0
Study 1689084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of endogenous opioids
Number of subjects: 0
Study 7028529 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (about 75 mg daily)
Number of subjects: 35
Study 7028529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31525164 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB + PA
Number of subjects: 213
Study 31525164 — intervention group
Group type: COMPARATOR
Intervention: PA
Number of subjects: 213
Study 26799308 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional retraining using a dot-probe task
Number of subjects: 74
Study 26799308 — intervention group
Group type: COMPARATOR
Intervention: Control training condition
Number of subjects: 74
Study 25986458 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 497
Study 25986458 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant prednisolone
Number of subjects: 497
Study 24519844 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous drainage (10 Fr drain placed subcutaneously connected to low pressure aspiration reservoir)
Number of subjects: 260
Study 24519844 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous drainage (control group)
Number of subjects: 260
Study 24519844 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous drainage
Number of subjects: 260
Study 24519844 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous drainage
Number of subjects: 260
Study 21955834 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mg/kg hydrocortisone infused over 30min
Number of subjects: 73
Study 21955834 — intervention group
Group type: COMPARATOR
Intervention: Saline infused over 30min (placebo)
Number of subjects: 73
Study 19200278 — intervention group
Group type: EXPERIMENTAL
Intervention: Support programme (self-monitoring, verbal reinforcement, motivation) in addition to exercise programme
Number of subjects: 0
Study 19200278 — intervention group
Group type: COMPARATOR
Intervention: Exercise programme only
Number of subjects: 0
Study 16217662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% dexamethasone‐cyclodextrin eye drop solution applied once daily
Number of subjects: 20
Study 16217662 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone sodium phosphate eye drops applied three times a day
Number of subjects: 20
Study 12820919 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with thoracic epidural analgesia (GEA)
Number of subjects: 20
Study 12820919 — intervention group
Group type: COMPARATOR
Intervention: Pure general anesthesia (GA)
Number of subjects: 20
Study 10849244 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem
Number of subjects: 8
Study 10849244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8651235 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported HIV sexual behaviors
Number of subjects: 246
Study 8651235 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported drug injection behaviors
Number of subjects: 246
Study 1794742 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PDN)
Number of subjects: 27
Study 1794742 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFC)
Number of subjects: 27
Study 6137292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study 6137292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (single-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (single-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (double-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (double-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (triple-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (triple-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (ejection fraction ≥ 0.50, single-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (ejection fraction ≥ 0.50, single-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (ejection fraction ≥ 0.50, double-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (ejection fraction ≥ 0.50, double-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (ejection fraction ≥ 0.50, triple-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (ejection fraction ≥ 0.50, triple-vessel disease)
Number of subjects: 780
Study 6137292 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (initially assigned)
Number of subjects: 780
Study 30947751 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg iron dextran (Cosmofer)
Number of subjects: 40
Study 30947751 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg iron sucrose (Venofer)
Number of subjects: 40
Study 30947751 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg iron isomaltoside (Monofer)
Number of subjects: 40
Study 30947751 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg iron isomaltoside (Monofer)
Number of subjects: 40
Study 30947751 — intervention group
Group type: COMPARATOR
Intervention: All iron preparations
Number of subjects: 40
Study 29135863 — intervention group
Group type: EXPERIMENTAL
Intervention: CROS
Number of subjects: 12
Study 29135863 — intervention group
Group type: COMPARATOR
Intervention: Bone-Anchored Implants (BAI)
Number of subjects: 12
Study 25692382 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leader modeling of healthy coping
Number of subjects: 706
Study 25692382 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leader modeling plus audience involvement to identify trusted adults
Number of subjects: 706
Study 25692382 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 706
Study 23184120 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise and hypocaloric healthy eating program
Number of subjects: 90
Study 20825805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB) - mean dosage 509 mg
Number of subjects: 44
Study 20825805 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (LZ) - mean dosage 4.2 mg
Number of subjects: 44
Study 20825805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 44
Study 20825805 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (LZ)
Number of subjects: 44
Study 18286484 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton transfer reaction-mass spectrometry for VOC analysis
Number of subjects: 22
Study 18286484 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 18286484 — intervention group
Group type: COMPARATOR
Intervention: High-risk patients
Number of subjects: 22
Study 18286484 — intervention group
Group type: COMPARATOR
Intervention: Posttherapy patients
Number of subjects: 22
Study 16527398 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain stimulation
Number of subjects: 0
Study 16527398 — intervention group
Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 0
Study 15175436 — intervention group
Group type: EXPERIMENTAL
Intervention: FL plus oxaliplatin
Number of subjects: 2246
Study 15175436 — intervention group
Group type: COMPARATOR
Intervention: FL alone
Number of subjects: 2246
Study 11673596 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 long-chain polyunsaturated fatty acids (LC-PUFA) from fish oil supplementation for 3 months
Number of subjects: 36
Study 11673596 — intervention group
Group type: COMPARATOR
Intervention: Untreated healthy children (control group)
Number of subjects: 36
Study 9467701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored antihypertensive educational intervention
Number of subjects: 130
Study 9467701 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonparticipating hypertensive workers)
Number of subjects: 130
Study 7964116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 0
Study 7964116 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 3215319 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective procedures
Number of subjects: 0
Study 3215319 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency procedures
Number of subjects: 0
Study 3215319 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical workload
Number of subjects: 0
Study 3215319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of abdominal aortic aneurysm
Number of subjects: 0
Study 29445029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (IV, 1.6 mg/kg over 4 hours) with Cisplatin (60 mg/m2 × 2 days per cycle)
Number of subjects: 12
Study 29445029 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (60 mg/m2 × 2 days per cycle) without Pantoprazole
Number of subjects: 12
Study 29445029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (IV, 1.6 mg/kg over 4 hours) with Cisplatin
Number of subjects: 12
Study 24726032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing low molecular weight heparin treatment for cancer-associated thrombosis
Number of subjects: 0
Study 24726032 — intervention group
Group type: COMPARATOR
Intervention: Cessation of low molecular weight heparin at six months treatment (current licensed practice)
Number of subjects: 0
Study 22994901 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg cyproheptadine (5‐HT antagonist)
Number of subjects: 12
Study 22994901 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram (SSRI)
Number of subjects: 12
Study 21174254 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental prosthetic foot with increased flexibility
Number of subjects: 14
Study 21174254 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental prosthetic foot with decreased flexibility
Number of subjects: 14
Study 21174254 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental prosthetic foot with greatest flexibility
Number of subjects: 14
Study 18760120 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate hydration (NaHCO(3))
Number of subjects: 1307
Study 18760120 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) hydration
Number of subjects: 1307
Study 16615374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentulo spiral mounted in a slow‐speed handpiece
Number of subjects: 24
Study 16615374 — intervention group
Group type: COMPARATOR
Intervention: Hand‐held lentulo spiral
Number of subjects: 24
Study 14498766 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlizumab (anti-IL-6 receptor antibody)
Number of subjects: 0
Study 10875526 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxy‐cholecalciferol vitamin D (0.25 mcg daily) and calcium (500 mg daily) for 9 months
Number of subjects: 20
Study 10875526 — intervention group
Group type: COMPARATOR
Intervention: Observation only (Control group)
Number of subjects: 20
Study 9170524 — intervention group
Group type: EXPERIMENTAL
Intervention: PFL-therapy (CDDP, 5-FU, and dl-LV)
Number of subjects: 26
Study 9170524 — intervention group
Group type: COMPARATOR
Intervention: FL-therapy (5-FU and dl-LV)
Number of subjects: 26
Study 1437426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed poisoning prevention packet (telephone stickers, coupon for syrup of ipecac, cabinet lock, checklist, pamphlets, cover letter)
Number of subjects: 336
Study 1437426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed poisoning prevention packet
Number of subjects: 336
Study 3555090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 16
Study 3555090 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 16
Study 3555090 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 16
Study 29330008 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent feedback
Number of subjects: 60
Study 29330008 — intervention group
Group type: COMPARATOR
Intervention: Non‐contingent feedback
Number of subjects: 60
Study 29330008 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 60
Study 26946313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid infusion (2g administered starting 30 minutes before anesthesia for 2 hours)
Number of subjects: 50
Study 26946313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered starting 30 minutes before anesthesia for 2 hours)
Number of subjects: 50
Study 26946313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid infusion
Number of subjects: 50
Study 26946313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24792937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin, 500 mg (every 6 hours for 7 days)
Number of subjects: 78
Study 24792937 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin, 300 mg (every 6 hours for 7 days)
Number of subjects: 78
Study 24792937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 6 hours for 7 days)
Number of subjects: 78
Study 24792937 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 78
Study 24792937 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility
Number of subjects: 78
Study 22981051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (one session a week for four weeks)
Number of subjects: 33
Study 22981051 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (10mg every night for four weeks)
Number of subjects: 33
Study 19568035 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 50 Hz
Number of subjects: 0
Study 19568035 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration (WBV) at 20 Hz and 35 Hz
Number of subjects: 0
Study 19568035 — intervention group
Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 0
Study 17549014 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus diagnosis of AOD by independent panel of neuropathologists
Number of subjects: 150
Study 17549014 — intervention group
Group type: COMPARATOR
Intervention: Local diagnosis of AOA
Number of subjects: 150
Study 17549014 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel diagnosis of AOD
Number of subjects: 150
Study 17549014 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD with 1p/19q loss
Number of subjects: 150
Study 17549014 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD without 1p/19q loss
Number of subjects: 150
Study 17549014 — intervention group
Group type: EXPERIMENTAL
Intervention: AOA without 1p/19q loss
Number of subjects: 150
Study 17549014 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of necrosis and presence of endothelial abnormalities
Number of subjects: 150
Study 17549014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' age, 1p/19q loss, and necrosis
Number of subjects: 150
Study 15139775 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-1697 dose 2 (loading dose 110 microg/kg i.v., infusion 1.0 microg/kg/min for 24 hours)
Number of subjects: 23
Study 15139775 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-1697 dose 1 (loading dose 55 microg/kg i.v., infusion 0.5 microg/kg/min for 24 hours)
Number of subjects: 23
Study 15139775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11773939 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 23000
Study 11773939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23000